J
Jurij Fürst
Researcher at Health Insurance Institute of Slovenia
Publications - 42
Citations - 1866
Jurij Fürst is an academic researcher from Health Insurance Institute of Slovenia. The author has contributed to research in topics: Health care & Biosimilar. The author has an hindex of 23, co-authored 38 publications receiving 1490 citations.
Papers
More filters
Journal ArticleDOI
Policies for biosimilar uptake in Europe: An overview.
Evelien Moorkens,Arnold G. Vulto,Isabelle Huys,Pieter Dylst,Brian Godman,Brian Godman,Simon Keuerleber,Barbara Claus,Maria Dimitrova,Guenka Petrova,Ljiljana Sović-Brkičić,Juraj Slabý,Robin Šebesta,Ott Laius,Allan Karr,Morgane Beck,Jaana E. Martikainen,Gisbert Selke,Susan Spillane,Laura McCullagh,Gianluca Trifirò,Patricia Vella Bonanno,Asbjørn Mack,Antra Fogele,Anita Viksna,Magdalena Władysiuk,Helder Mota-Filipe,Dmitry Meshkov,Marija Kalaba,Simona Mencej Bedrač,Jurij Fürst,Corrine Zara,Peter Skiold,Einar Magnusson,Steven Simoens +34 more
TL;DR: Most countries have put in place specific supply-side policies for promoting access to biosimilars, but investments should be made to clearly communicate on biosimilarars and educate stakeholders to support a sustainable biosimilar market.
Journal ArticleDOI
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems
Brian Godman,Rickard E. Malmström,Eduardo Diogene,Andy Gray,Sisira Jayathissa,Angela Timoney,Francisco de Assis Acurcio,Ali Alkan,Anna Brzezinska,Anna Bucsics,Stephen Campbell,Jadwiga Czeczot,Winnie de Bruyn,Irene Eriksson,Faridah Yusof,Alexander E. Finlayson,Jurij Fürst,Kristina Garuoliene,Augusto Afonso Guerra Junior,Jolanta Gulbinovič,Saira Jan,Roberta Joppi,Marija Kalaba,Einar Magnisson,Laura McCullagh,Kaisa Miikkulainen,Gabriela Ofierska-Sujkowska,Hanne Bak Pedersen,Gisbert Selke,Catherine Sermet,Susan Spillane,Azuwana Supian,Ilse Truter,Vera Vlahović-Palčevski,Low Ee Vien,Elif Hilal Vural,Janet Wale,Magdalene Wladysiuk,Wenjie Zeng,Lars L. Gustafsson +39 more
TL;DR: The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines, as well as develop exemplar models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure.
Journal ArticleDOI
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.
Brian Godman,Brian Godman,Brian Godman,Björn Wettermark,Björn Wettermark,Menno van Woerkom,Jessica Fraeyman,Samantha Alvarez-Madrazo,Christian Berg,Iain Bishop,Anna Bucsics,Stephen Campbell,Alexander E. Finlayson,Jurij Fürst,Kristina Garuoliene,Harald Herholz,Marija Kalaba,Ott Laius,Jutta Piessnegger,Catherine Sermet,Ulrich Schwabe,Vera Vlahović-Palčevski,Vanda Marković-Peković,Vanda Marković-Peković,Luka Vončina,Kamila Malinowska,Corinne Zara,Lars L. Gustafsson +27 more
TL;DR: Analysis of retrospective observational studies on reimbursed use and expenditure of PPIs, statins, and renin-angiotensin inhibitor drugs among European countries suggests multiple demand-side measures are needed to influence prescribing patterns.
Journal ArticleDOI
Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future
Brian Godman,Mainul Haque,Judy McKimm,Muhamad Abu Bakar,Jacqueline Sneddon,Janney Wale,Stephen Campbell,Antony P. Martin,Iris Hoxha,Vafa Abilova,Bene D. Anand Paramadhas,Pinkie Mpinda-Joseph,Matshediso Matome,Lívia Lovato Pires de Lemos,Israel Abebrese Sefah,Amanj Kurdi,Sylvia Opanga,Arianit Jakupi,Zikria Saleem,Mohamed Azmi Hassali,Dan Kibuule,Joseph O Fadare,Tomasz Bochenek,Celia C. Rothe,Jurij Fürst,Vanda Marković-Peković,Ljubica Bojanić,Natalie Schellack,Johanna C Meyer,Zinhle Matsebula,Thuy Nguyen Thi Phuong,Binh Nguyen Thanh,Saira Jan,Aubrey Chichonyi Kalungia,Sekesai Mtapuri-Zinyowera,Massimo Sartelli,Ruaraidh Hill +36 more
TL;DR: There is a need to document current practices and successful initiatives in LMICs to improve future antimicrobial use, and initiatives to reduce inappropriate prescribing and dispensing of antimicrobials for URTIs as part of NAPs and other activities, are monitored.
Journal ArticleDOI
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Brian Godman,Anna Bucsics,Patricia Vella Bonanno,Wija Oortwijn,Wija Oortwijn,Celia C. Rothe,Alessandra Ferrario,Simone Bosselli,Andrew Hill,Antony P. Martin,Steven Simoens,Amanj Kurdi,Amanj Kurdi,Mohamed Gad,Jolanta Gulbinovič,Angela Timoney,Angela Timoney,Tomasz Bochenek,Ahmed Salem,Iris Hoxha,Robert Sauermann,Amos Massele,Augusto Alfonso Guerra,Guenka Petrova,Zornitsa Mitkova,Gnosia Achniotou,Ott Laius,Catherine Sermet,Gisbert Selke,Vasileios Kourafalos,John Yfantopoulos,Einar Magnusson,Roberta Joppi,Margaret Oluka,Hye Young Kwon,Arianit Jakupi,Francis Kalemeera,Joseph O Fadare,Øyvind Melien,Maciej Pomorski,Magdalene Wladysiuk,Vanda Marković-Peković,Vanda Marković-Peković,Ileana Mardare,Dmitry Meshkov,Tanja Novakovic,Jurij Fürst,D Tomek,Corrine Zara,Eduardo Diogene,Johanna C Meyer,Rickard E. Malmström,Björn Wettermark,Björn Wettermark,Zinhle Matsebula,Stephen Campbell,Alan Haycox +56 more
TL;DR: The primary aim of this paper is to consider potential ways to optimize the use of new medicines balancing rising costs with increasing budgetary pressures to stimulate debate especially from a payer perspective.